منابع

 1) Bruni L et al. Cervical human papillomavirus prevalence in 5 continents: meta-ana­lysis of 1 million women with normal cytological findings. J Infect Dis, 2010;202(12):1789–1799
https://academic.oup.com/jid/article/202/12/1789/2192082

2) Greer CE et al. Human papillomavirus (HPV) type distribution and serological res­ponse to HPV type 6 virus-like particles in patients with genital warts. J Clin Micro­biol, 1995;33(8):2058–2063.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC228335/

3) Gardasil 9. Food and Drug Administration. Available at https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf, ac­cessed February 2017.

4) http://www.who.int/wer

5) Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12.
https://www.ncbi.nlm.nih.gov/pubmed/10451482

6) Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, Razzaghi H, Saraiya M, Centers for Disease Control and Prevention (CDC). Human papillomavirus–associated cancers United States, 2008–2012. MMWR 2016;65(26):661–666.
https://www.ncbi.nlm.nih.gov/pubmed/27387669

7) Plummer M et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016; 4: e609–16.
https://www.ncbi.nlm.nih.gov/pubmed/27470177 

8) Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, Razzaghi H, Saraiya M, Centers for Disease Control and Prevention (CDC). Human papillomavirus–associated cancers—United States, 2008–2012. MMWR 2016;65(26):661–666.
https://www.ncbi.nlm.nih.gov/pubmed/27387669 

9) De Martel C et al. Worldwide burden of cancer attributable to HPV by site, country

and HPV type. IJC 2017 [in Press].
https://www.ncbi.nlm.nih.gov/pubmed/28369882 

10) HPV vaccine background
http://www.who.int/immunization/sage/meetings/2016/october/1_HPV_vaccine_background_document_27Sept2016.pdf?ua=1

11) De Martel C et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. IJC 2017 [in Press].
https://www.ncbi.nlm.nih.gov/pubmed/28369882

12)  Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. Available at http://www.who.int/vaccine_safety/committee/to­pics/hpv/GACVS_Statement_HPV_12_Mar_2014.pdf?ua=1, accessed February 2017.

13) Background documents and presentations presented during the SAGE meeting in October 2016. Available at http://www.who.int/immunization/sage/meetings/2016/ october/presentations_background_docs/en/, accessed February 2017.

14) Reiter PL et al. How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen. Vaccine. 2009 Nov 16; 27(49): 6840–6844.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016947/

15) Einstein MH et al. Comparative immunogenicity and safety of human papillomavi­rus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin, 2011; 7: 1343–1358.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338932/

16) Joura EA et al. A 9-valent HPV vaccine against infection and intraepithelial neopla­sia in women. NEJM 2015;372(8):711–723.
https://www.nejm.org/doi/10.1056/NEJMoa1405044?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov&

17) Grading of scientific evidence – table VIII: Safety of HPV vaccination in young females. Available at http://www.who.int/immunization/position_papers/hpv_grad_safety.pdf, accessed February 2017.

18) Moreira ED et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics.2016;138(2).
http://pediatrics.aappublications.org/content/138/2/e20154387.long

19) Andrews N. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine. 2017 Mar 23;35(13):1729 1732.
https://www.ncbi.nlm.nih.gov/m/pubmed/28245941/

20) Angelo MG et al. Post-licensure safety surveillance for human papillomavi­rus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoe­pidemiol Drug Saf, 2014;23(5):456–465.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265196/

21) de Sanjose S et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.  Lancet Oncology, 2010;11:1048–1056.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70230-8/fulltext

22) Kreimer AR et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst, 2011;103:1444–1451.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186781/

23) Basu P et al. Less than 3 doses of the HPV vaccine – Review of efficacy against viro­logical and disease end points. Hum Vaccin Immunother 2016; 12:1394-1402.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964672/

24) Sankaranaarayanan R et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 2016; 17: 67–77.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357737/

25) Markowitz LM et al. High effectiveness after vaccine type prevalence after 1, 2 and 3 doses of quadrivalent HPV vaccine, United States. HPV 2017, 2 March 2017.
https://www.google.com/urlsa=t&source=web&rct=j&url=http://www.who.int/immunization/policy/position_papers/pp_hpv_may2017_ref_list.pdf&ved=2ahUKEwiMwt6A2L_bAhUnqlkKHWcVB4kQFjADegQIBhAB&usg=AOvVaw0RqWSuHZT0nrzT1sLb0jeT

26) HPV vaccine background document. Available at http://www.who.int/immunization/sage/meetings/201 october/1_HPV_vaccine_background_ document_27Sept2016.pdf?ua=1,  accessed February 2017.

27) WHO guidelines: use of cryotherapy for cervical intraepithelial neoplasia. World Health Organization, Geneva, 2011. Available at http://whqlibdoc.who.int/publica­tions/2011/9789241502856_eng.pdf?ua=, accessed February 2017.

28) International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses. Vol. 90. Lyon, IARC, 2007. Available at http://monographs.iarc.fr/ENG/Monographs/vol90/mono90.pdf, accessed February 2017.

29) Safaeian M et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res, 2013; 6:1242–1250.
http://cancerpreventionresearch.aacrjournals.org/content/6/11/1242.long

30) Malagon T et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta- analysis. Lancet Infect Dis, 2012;12:781–789.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(12)70187-1/fulltext

31) Kemp TJ et al. HPV16/18 L1 VLP vaccine induces cross-neutralising antibodies that may mediate cross-protection. Vaccine 2011;29(11):2011–2014.
https://www.sciencedirect.com/science/article/pii/S0264410X1100017X?via%3Dihub

World Health OrganizationWeekly epidemiological record

Universal vaccination with
the quadrivalent HPV vaccine
in Austriaimpact on virus
circulation, public health and
cost–effectiveness analysis